MA58643B1 - Composés anticancéreux - Google Patents

Composés anticancéreux

Info

Publication number
MA58643B1
MA58643B1 MA58643A MA58643A MA58643B1 MA 58643 B1 MA58643 B1 MA 58643B1 MA 58643 A MA58643 A MA 58643A MA 58643 A MA58643 A MA 58643A MA 58643 B1 MA58643 B1 MA 58643B1
Authority
MA
Morocco
Prior art keywords
cancer compounds
cancer
compounds
compound
take
Prior art date
Application number
MA58643A
Other languages
English (en)
Inventor
Maria Del Carmen Cuevas Marchante
Andrés Francesch Solloso
Valentin Martinez Barrasa
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MA58643B1 publication Critical patent/MA58643B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Composé de formule générale id, dans laquelle x, r1-r4 prennent diverses significations, destiné à être utilisé dans le traitement du cancer.
MA58643A 2017-04-27 2018-04-27 Composés anticancéreux MA58643B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17382228 2017-04-27

Publications (1)

Publication Number Publication Date
MA58643B1 true MA58643B1 (fr) 2023-09-27

Family

ID=58668823

Family Applications (3)

Application Number Title Priority Date Filing Date
MA48455A MA48455B1 (fr) 2017-04-27 2018-04-27 Composés antitumoraux
MA57420A MA57420B1 (fr) 2017-04-27 2018-04-27 Composés anticancéreux
MA58643A MA58643B1 (fr) 2017-04-27 2018-04-27 Composés anticancéreux

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA48455A MA48455B1 (fr) 2017-04-27 2018-04-27 Composés antitumoraux
MA57420A MA57420B1 (fr) 2017-04-27 2018-04-27 Composés anticancéreux

Country Status (2)

Country Link
AR (1) AR114387A1 (fr)
MA (3) MA48455B1 (fr)

Also Published As

Publication number Publication date
AR114387A1 (es) 2020-09-02
MA48455A (fr) 2020-03-04
MA57420B1 (fr) 2023-06-28
MA48455B1 (fr) 2023-06-28

Similar Documents

Publication Publication Date Title
MA44020B1 (fr) Composés antitumoraux
CY1121938T1 (el) Αγωνιστες apj 4-υδροξυ-3-(ετερο¶ρυλ)πυριδινο-2-ονης για χρηση στη θεραπεια καρδιαγγειακων διαταραχων
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
MA44734A (fr) Composés et compositions destinés au traitement d'états associés à une activité de nlrp
EP3013345A4 (fr) Composés pour le traitement d'une amyotrophie spinale
CY1119361T1 (el) 3,4-διυδροισοκινολιν-2(1h)-υλικες ενωσεις
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
EP3455205A4 (fr) Peptidomimétiques pour le traitement d'une infection à norovirus
MX380907B (es) Compuestos útiles como inhibidores de cinasa.
EA201790271A1 (ru) Ингибиторы гликозидазы
MA40221A (fr) Dérivés d'isoindoline à utiliser dans le traitement d'une infection virale
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MX2018010191A (es) Inhibidores de glucosidasa.
MA38826B1 (fr) Nouveaux dérivés de triazolo[4,5-d]pyrimidine
MA38404A1 (fr) Nouveaux dérivés de pyridine
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
EP3520785A4 (fr) Utilisation d'une formule renfermant un agent bactériostatique pour la préparation d'un composé à application vaginale et ledit composé
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
MA43400B1 (fr) Dérivés de phényle en tant qu'agonistes du récepteur cannabinoïde 2
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
EA201891240A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
MA39305A3 (fr) Dérivés d'éthynyle
MA58643B1 (fr) Composés anticancéreux